HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma

NCT03216499 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

DRUG: HIF-2alpha Inhibitor PT2385
OTHER: Pharmacological Study
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacogenomic Study

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]